drugset / Trial / NCT02256735

Study to Investigate the Effect of KUC 7483 CL on the QT/QTc Interval of the ECG in Comparison to Placebo and Moxifloxacin in Healthy Male and Female Volunteers

NCT02256735

Phase 1 Completed 39 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to investigate the effect of Ritobegron CL (KUC 7483 CL) on the QT/QTc interval of the ECG in comparison to placebo and moxifloxacin

Timeline

Start
2005-08
Primary completion
2005-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Moxifloxacin Small molecule
Subject Ritobegron Small molecule 40 mg Oral
Subject Ritobegron Small molecule 80 mg Oral
Subject Ritobegron Small molecule 160 mg Oral
Subject Ritobegron Small molecule 320 mg Oral

Indications

No indication recorded.